Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.